Ambros Therapeutics initiates Phase 3 trial of AMBTX-01 for CRPS Type 1
Ambros Therapeutics has launched Phase 3 clinical trial evaluating AMBTX-01 (neridronate) for the treatment of Complex Regional Pain Syndrome Type 1.
Asset / Drug
Drug and asset intelligence for AMBTX-01 with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.